Prevalence of neutralizing antibody to respiratory syncytial virus in sera from mothers and newborns residing in the Gambia and in The United States

Suara, Rahaman O.; Piedra, Pedro A.; Glezen, W. Paul; Adegbola, R A; Weber, Martin; Mulholland, E. Kim; Greenwood, Brian; Whittle, H.C.

doi:10.1128/cdli.3.4.477-479.1996

Cited by 32 publications

(17 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results are slightly lower compared to those found in a recent study conducted in Bangladesh [19] . However, other studies reported neutralising antibody titres lower than our estimates [20,21] . We also found that, the cord antibody level is related to birthweight and gestational period; which are some of the factors reported to influence transplacental antibody transfer [22] .…”

Section: Discussioncontrasting

confidence: 93%

Quantifying maternally derived respiratory syncytial virus specific neutralising antibodies in a birth cohort from coastal Kenya

Nyiro

Sande

Mutunga

et al. 2015

Vaccine

View full text Add to dashboard Cite

show abstract

Section: Discussioncontrasting

confidence: 93%

Quantifying maternally derived respiratory syncytial virus specific neutralising antibodies in a birth cohort from coastal Kenya

Nyiro

Sande

Mutunga

et al. 2015

Vaccine

View full text Add to dashboard Cite

show abstract

“…Therefore, pertussis vaccines in pregnancy are administered in the third trimester to maximize transplacental antibody transfer to the infant [ 19 ]. RSV transplacental antibody transfer is efficient in mother-infant pairs in South Asia, the United States, and the Gambia [ 20 ]. Higher cord blood RSV antibody titers in Bangladesh are associated with decreased risk of serologic infection in infants [ 21 ].…”

Section: Discussionmentioning

confidence: 99%

Clinical Presentation and Birth Outcomes Associated with Respiratory Syncytial Virus Infection in Pregnancy

et al. 2016

View full text Add to dashboard Cite

BackgroundRespiratory syncytial virus (RSV) is the most important cause of viral pneumonia in children worldwide. A maternal vaccine may protect both the mother and infant from RSV illness. The epidemiology and clinical presentation of RSV in pregnant and postpartum women is not well-described.MethodsData were collected from a prospective, randomized trial of influenza immunization in pregnant women in rural southern Nepal. Women were enrolled in their second trimester of pregnancy and followed until six months postpartum. Active weekly home-based surveillance for febrile respiratory illness was performed. Mid-nasal swabs collected with episodes of respiratory illness were tested for RSV by real-time polymerase chain reaction.ResultsRSV was detected in 14 (0.4%) illness episodes in 3693 women over 3554 person-years of surveillance from 2011–2014. RSV incidence was 3.9/1000 person-years overall, and 11.8/1000 person-years between September and December. Seven (50%) women sought care for RSV illness; none died. Of the 7 (50%) illness episodes during pregnancy, all had live births with 2 (29%) preterm births and a median birthweight of 3060 grams. This compares to 469 (13%) preterm births and a median birthweight of 2790 grams in women without RSV during pregnancy. Of the 7 mothers with postpartum RSV infection, RSV was detected in 4 (57%) of their infants.ConclusionsRSV was an uncommon cause of febrile respiratory illness in mothers during pregnancy in Nepal. These data will inform prevention and therapeutic strategies against RSV in resource-limited settings.

show abstract

“…Passively acquired IgG RSV antibodies decline progressively during the first months of life, with a halflife of 26 days [Brandenburg et al, 1997]. Data from developing countries are scarce but would indicate that transmission of antibodies across the placenta and the kinetics of antibody decline are similar to those in developed regions [Suara et al, 1996].…”

Section: Introductionmentioning

confidence: 99%

Prevalence of respiratory syncytial virus IgG antibodies in infants living in a rural area of Mozambique

Roca

Abacassamo

Loscertales

et al. 2002

Journal of Medical Virology

View full text Add to dashboard Cite

A case control study was carried out in Manhiça (Mozambique). Serum samples were collected from infants < 1 year of age in hospital to assess the effect of serum antibodies on the incidence of respiratory syncytial virus (RSV) infection. Sera were collected from a total of 31 cases of RSV infection and paired uninfected controls matched for age and sex. Anti-RSV antibodies were assessed by a membrane fluorescent antibody test (MFAT) for immunoglobulin G (IgG) antibodies and by a neutralizing antibody test. IgG RSV antibodies were of higher prevalence and at higher levels in the control group when compared to the infected case group (P < 0.001), indicating an important role for IgG antibodies in protection. To assess infection before recruitment, IgA RSV antibodies were also measured by MFAT. IgA RSV antibody prevalence was very low in patients and controls (0/31 and 4/31 respectively), suggesting that most of the detected IgG RSV antibody in both groups was of maternal origin. Re-analysis of data from the subset of 27 matched, IgA RSV antibody negative infant pairs mirrored the full analysis indicating that maternal antibody has an important role in RSV protection. Similar results were obtained when neutralizing antibodies were measured and when the measurement was done against subgroup A virus strain A2, subgroup B virus strain 8/60 and a contemporary subgroup A isolate, Moz00. No significant differences in the reactivity of maternal antibodies with the three virus strains were observed. The data described below represent the first analysis of the role of maternal antibodies in reducing the risk of pediatric infection in developing countries. The results reinforce the concept of maternal vaccination for the control of RSV in very young children in whom the risk and severity of infection are the highest.

show abstract

Prevalence of neutralizing antibody to respiratory syncytial virus in sera from mothers and newborns residing in the Gambia and in The United States

Cited by 32 publications

References 17 publications

Quantifying maternally derived respiratory syncytial virus specific neutralising antibodies in a birth cohort from coastal Kenya

Quantifying maternally derived respiratory syncytial virus specific neutralising antibodies in a birth cohort from coastal Kenya

Clinical Presentation and Birth Outcomes Associated with Respiratory Syncytial Virus Infection in Pregnancy

Prevalence of respiratory syncytial virus IgG antibodies in infants living in a rural area of Mozambique

Contact Info

Product

Resources

About